Gland Pharma Ltd. - Research Center
543245 GLAND Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | |
|---|---|---|---|---|---|
| Sales | 3,462.88 | 2,633.24 | 2,044.20 | 1,619.94 | 1,479.18 |
| Operating profit | 1,302.27 | 955.47 | 706.31 | 535.11 | 624.99 |
| Interest | 3.41 | 7.18 | 3.56 | 4.13 | 6.39 |
| Gross profit | 1,433.63 | 1,087.45 | 788.32 | 579.77 | 652.16 |
| EPS (Rs) | 60.95 | 49.88 | 29.16 | 20.72 | 26.70 |
Annual
results in details
| Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | |
|---|---|---|---|---|---|
| Other income | 134.78 | 139.17 | 85.56 | 48.79 | 33.56 |
| Stock adjustment | -273.49 | -6.90 | -114.15 | -66.67 | 46.37 |
| Raw material | 1,749.16 | 1,090.25 | 954.89 | 718.30 | 450.67 |
| Power and fuel | 74.59 | - | - | - | - |
| Employee expenses | 311.36 | 277.66 | 222.95 | 179.08 | 153.42 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 298.99 | 316.76 | 274.21 | 254.12 | 203.73 |
| Provisions made | - | - | - | - | - |
| Depreciation | 98.78 | 94.59 | 81.96 | 78.21 | 74.15 |
| Taxation | 337.85 | 220.01 | 234.45 | 180.45 | 164.29 |
| Net profit / loss | 997.01 | 772.86 | 451.91 | 321.11 | 413.73 |
| Extra ordinary item | - | - | -20.00 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 16.36 | 15.50 | 15.50 | 15.50 | 15.50 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 37.61 | 36.28 | 34.55 | 33.03 | 42.25 |
| GPM (%) | 39.85 | 39.22 | 37.01 | 34.74 | 43.11 |
| NPM (%) | 27.71 | 27.88 | 21.22 | 19.24 | 27.35 |
Mutual Fund Selector
Find the fund that is right for you
© 2021 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis